glp-1 agonists addiction Medications Get at the Heart of Addiction: Study Hype Or Hope? Latest Research

Whether you're on a GLP-1 medication and want complementary support, or you're taking the natural route entirely, this patch was made for you

Learn about the latest science behind GLP-1 weight loss drugs, the nutritional needs of GLP-1 users and what this means for future innovation in food and beverage.

A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss

Recent signals underscore this shift: Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization [1] buoyed by global demand for obesity medications

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

For users this could segway into an expansion of the private market and for payers this could provide an affordable entry point for public reimbursement